Introduction
Influenza viral illness, like many other microbial diseases, can be prevented through vaccination. However, vaccine development against infectious diseases such as influenza is often a challenge because multiple isotypes and strains exist. Furthermore, new strains, including potentially pandemic strains, are continuously emerging. Hence, simple monovalent vaccine formulations for these pathogens and their derivatives are not sufficient for long-term control. Development of multivalent formulations for broad-range reactivity and protection is crucial.
Conserved epitopes, including regions of haemagglutinin (HA), nucleoprotein, or matrix protein 2 (M2) of influenza virus can elicit heterosubtypic immunity. [1] [2] [3] HA is the major surface antigen on influenza virus and is composed of HA1 and HA2 subunits. The HA1 region is highly variable among influenza A strains, whereas HA2 is more conserved. HA2-specific antibodies reduce the replication of influenza by inhibiting fusion 4 and providing protection in mice. 5, 6 M2 of influenza A virus is a tetrameric ion channel protein that is targeted by the antivirals amantadine and rimantadine. 7 The N-terminal, 23-amino-acid peptide of M2 (M2e) is highly conserved among all influenza A viruses. 8 Antibodies against M2 reduce viral spread, 9 and virus-like particles containing M2 or M2e elicit cross-strain reactive antibodies, specific T-cell responses, and confer heterosubtypic protection in mice. [10] [11] [12] [13] [14] Because influenza virus is a respiratory pathogen, intranasal delivery of these conserved, immunogenic antigens may be ideal.
For an effective, intranasal vaccine strategy, a compatible adjuvant system is essential. Detoxified anthrax toxins can be used as adjuvants for vaccine development. [15] [16] [17] [18] [19] An additional advantage to this approach is the induction of protective immunity against anthrax, another infectious biological agent with urgency for an improved vaccine strategy. Anthrax is a severe infectious disease caused by Bacillus anthracis, which produces a tripartite exotoxin comprised of protective antigen (PA), lethal factor (LF),
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and oedema factor (EF). PA in combination with EF forms oedema toxin (EdTx), and PA in combination with LF forms lethal toxin (LeTx). Individually, PA, EF and LF are non-toxic. PA mediates entry of EF and LF into the cytosol of susceptible cells by receptor-mediated endocytosis. The N-terminal region of EF (EFn) is critical for binding to PA and subsequent translocation into cytosol. EFn (1-254 residues) lacks cytotoxicity, but its antigenicity is preserved, and can potentially be used in the formulation of a mucosal vaccine against anthrax. [20] [21] [22] [23] Vaccination with the current licensed vaccine BioThrax TM , an aluminium hydroxide-adsorbed supernatant material from fermentor cultures of a toxigenic, non-encapsulated strain of B. anthracis, requires a lengthy and complicated schedule: five intramuscular injections (0 and 4 weeks, then 6, 12 and 18 months) followed by annual boosters. 24 Hence, the current approach is inadequate in the case of a bioterrorist attack with anthrax.
In this study, we designed a vaccine based on conserved influenza antigens, in combination with an anthrax antigen delivery system. The ultimate goal is to create a dual vaccine that would provide broad cross-strain protection across various influenza virus subtypes, while also eliciting protective immunity against anthrax. Multiple vaccine formulations were evaluated in mice for their abilities to confer humoral, T-cell and protective immunities.
Materials and methods

Vaccine candidate design, production and purification
For 39M2e-HA2 antigen design, we aligned HA2 of H1N1, H3N2, H5N1, H7N1, H7N3 and H9N2 amino acid gene sequences from the the NCBI Influenza Virus Resource. The most common amino acids in each position were used to create an artificial, centralized, HA2 sequence. Next, a tandem of M2es from A/California/04/ 2009 (H1N1), A/Hong Kong/1/1968 (H3N2) and A/Vietnam/1204/2004 (H5N1) influenza viruses was created and linked with the centralized HA2 as previously described. 25 The anthrax EFn gene sequence 20 was added upstream of the 39M2e-HA2 (Table 1 ). In addition, Ala-Ala-Ala or Gly-Ser linkers were designed in between individual gene segments. The artificial gene sequence was codon-optimized for Escherichia coli and synthesized by GenScript, Inc. (Piscataway, NJ). The full-length, avian influenza A (H5N1) M2 DNA sequence was synthesized by Retrogen, Inc. (San Diego, CA). M2, 39M2e-HA2, and EFn39M2e-HA2 genes were inserted into prokaryotic plasmid pET200/D-TOPO (Life Technologies, Carlsbad, CA). For EFn-M2, the EFn sequence was cloned upstream of the full-length M2 sequence in the pET200/D-TOPO plasmid. All expression plasmids were transformed in BL21 Star TM (DE3) competent cells (Life Technologies). Transformed cells were cultured in Luria-Bertani medium with 50 lg/ml of kanamycin to an optical density at 600 nm of 0Á5, and expression was induced with 0Á001-1 mM Isopropyl b-D-1-thiogalactopyranoside depending on the protein, and harvested 2-4 hr later. The expressed proteins contained 69His tags and were purified by affinity chromatography using Ni-NTA agarose beads. For M2, 39M2e-HA2 and EFn-39M2e-HA2, purifications were performed with denaturing buffer: 100 mM NaH 2 PO 4 , 10 mM Tris-HCl and 8 M urea with varying imidazole concentrations of 10-250 mM (all pH 8). EFn-M2 was purified with native buffer: 10 mM Tris-HCl, 0Á1 mM EDTA, and 500 mM NaCl with varying imidazole concentrations of 10-250 mM (all pH 8). Purified proteins were dialysed and concentrated using ultracentrifugal filter devices (Millipore, Billerica, MA) with dialysis buffer: PBS with 10% glycerol. Proteins were stored at À80°b efore use for vaccination. Antigen sequences and vaccine candidate designs are shown in Table 1 and Fig. 1(a) , respectively. Proteins were verified by Western blot (Fig. 1b) using anti-His-G-AP (Life Technologies), rabbit anti-Avian influenza M2 (Thermo Scientific, Lafayette, CO), or rabbit anti-EF (gift from Dr Stephen Leppla).
Immunization of mice and serum collection
All mice in these studies were housed in the LARC facility of Texas Tech University Health Sciences Center El Paso. All studies were approved by the Institutional Animal Care and Use Committee. BALB/c mice (6-8 weeks) were purchased from Harlan Laboratories (Indianapolis, IN). Before intranasal immunization with vaccine candidates, mice were anaesthetized via intraperitoneal injection of 100 µl of 80 mg/kg ketamine and 6 mg/kg xylazine. Groups of mice were then immunized via intranasal administration of 20-30 ll of the following: (i) 30 lg M2, (ii) 30 lg EFn-M2, (iii) 30 lg EFn-M2 with 60 lg PA, (iv) 30 lg EFn-39M2e-HA2, (v) 30 lg EFn-39M2e-HA2 with 60 lg PA, or (vi) PBS. Recombinant PA purified from E. coli was obtained from BEI Resources (Manassas, VA) and was mixed with EFn-M2 or EFn39M2e-HA2 before immunization of mice and allowed to incubate with these components for at least 10 min at room temperature. Mice were immunized at 0, 2 and 5 weeks. Mice were bled just before each immunization, and on week 7 via the submandibular method with 5-mm lancets. Additional experiments were conducted in the same manner in wild-type, CD4 knockout (KO), and CD8 KO C57BL/6 mice (The Jackson Laboratory, Bar Harbor, ME).
ELISA
To measure antigen-specific antibody responses in the sera of naive and immunized mice ELISAs were performed. Ninety-six-well Corning (Corning, NY) were coated with 1 lg/ml of recombinant antigens: M2, 39M2e-HA2, EF, HA2, HA2-region peptides, or PA at 4°overnight. EF, HA and HA2-region peptides were all obtained from BEI Resources. The plates were washed five times with PBS-T (PBS with 0Á05% Tween-20) by the ImmunoWash TM 1575 microplate washer (Bio-Rad, Hercules, CA), then blocked with 1% bovine serum albumin (BSA) in PBS for 1 hr at room temperature. Serum samples were diluted at 1 : 50 in 100 ll PBS-T per well and were incubated for 2 hr at room temperature with rocking. After washing, secondary anti-mouse IgG-Fc, IgG1, and IgG2a were diluted at 1 : 10 000 in PBS-T and used at 100 ll/well. After 1 hr of incubation at room temperature with rocking, the plates were washed again. Bound antibody was detected using the p-nitrophenylphosphate phosphatase substrate 
Influenza virus microneutralization assay
Microneutralization was performed as previously described 4 with some modifications. Briefly, mouse sera were heat-inactivated at 56°for 30 min, and two-fold serial dilutions were prepared. Fifty microlitres of each dilution was added to one well of a microtitre plate and mixed with 50 ll (2 9 10 4 plaque-forming units) of H1N1 influenza virus A/PR/8/34 (PR8, from VR-95; ATCC, Manassas, VA). The plate was incubated for 1 hr at 37°, and 50 ll of the suspension was transferred onto Madin-Darby canine kidney (MDCK) cells. After 1 hr of incubation at 37°in 5% CO 2 , the suspension with the virus and antibody was removed and 1% agarose in medium (minimum essential medium, 0Á2% BSA, 1 lg/ml TPCK-trypsin) was added to each well. After 18-20 hr, the agarose was removed and the cells were fixed with ethanol and stained with Coomassie Blue.
Lethal challenge with influenza viruses
Mice were challenged with H1N1 influenza virus PR8 2 weeks after administration of the third vaccine dose. Each mouse was weighed first, then anaesthetized with ketamine and xylazine, and given 2 9 10 5 PFU of live A/ PR/8/34 in 40 ll intranasally. Mice were monitored for signs of illness and weighed for 21 days post-inoculation at the same time each day. Death was considered an endpoint for survival analysis. A different group of experimental mice was challenged intranasally with 1 9 10 5 PFU of live A/CA/4/09 in 40 ll. Mice were monitored as before, and death, or 30% weight loss was considered an endpoint for survival analysis.
Anthrax lethal toxin neutralization assay
Toxin neutralization assays were performed as we have previously described. [20] [21] [22] [23] Sera from mice were evaluated for the ability to neutralize anthrax LeTx. Serial dilutions of sera were incubated with 320 ng/ml recombinant LF purified from B. anthracis (BEI Resources) in PBS for 1 hr. Next, recombinant PA purified from B. anthracis (BEI Resources) was added at 480 ng/ml and incubated for 1 hr. The above solutions were then added to Raw 264.7 murine macrophage cells in 96-well plates at 100 ll/well and were incubated for 7 hr at 37°and 5% CO 2 . In parallel, viablecell control samples were incubated with 100 ll/well PBS.
To assess cell viability, we employed a thiazolyl blue tetrazolium bromide (MTT) colorimetric assay as described by Twentyman et al., 26 with some modification. Briefly, 20 µl of MTT was added to each well and incubated for 2 hr at 37°and 5% CO 2 . Then, the medium was carefully removed and 200 µl/well of dimethyl sulphoxide was added to solubilize the formazan crystals formed. Absorbances were measured at 570 nm using the PowerWave XS2 plate reader with GEN5 software. Readings were normalized to viable-cell control samples for each experiment.
Lethal challenge with B. anthracis Sterne spores
A/J (6-8 weeks) mice were purchased from Jackson Laboratories. These mice are complement-deficient, and so are susceptible to lethal challenge with Anthrax Sterne spores, unlike BALB/c and C57BL/6 mice. Groups of mice were intranasally immunized three times with 30 lg EFn39M2e-HA2 plus 60 lg PA, or subcutaneously immunized once with 50 spores from the Colorado Serum Company's anthrax spore vaccine (Denver, CO). Two weeks after the final immunizations, mice were subcutaneously challenged with 5 9 10 4 -1Á8 9 10 5 spores. Mice were monitored for signs of illness and weighed for up to 14 days post-inoculation.
Analysis of T-cell immune responses by detection of stimulated T-cell population and intracellular cytokine staining
Mice were killed using cervical dislocation and spleens were collected into microcentrifuge tubes containing Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% heat-inactivated fetal bovine serum, 100 U/ml penicillin and 100 lg/ml streptomycin (DMEM-10). Spleen cells were mechanically isolated by straining through 100-lm nylon mesh cell strainers. Red blood cells were removed using ACK lysis buffer followed by a washing step. The splenic mononuclear cells were used for experiments at 2 9 10 6 cells/ml in 0Á5 ml DMEM-10/ well. These cells were left untreated or stimulated with 10 lg/ml of the following antigens: phytohaemagluttinin or 10 ng of PMA/100 ng ionomycin (Sigma-Aldrich, St Louis, MO) as positive controls, M2, 39M2e-HA2, PA, M2e region peptides from A/New York/348/03 (H1N1) M2 peptide array (NR-2614; BEI Resources), HA2 region peptides from A/California/04/2009 (H1N1) HA peptide array (NR-19244; BEI Resources), or recombinant EF (NR-13413; BEI Resources). To analyse the stimulation of the T-cell population, the splenocytes were cultured for 5 days in the presence of antigens. For intracellular cytokine staining, the GolgiStop transport inhibitor (BD Biosciences, San Jose, CA) was added to spleen cell cultures in the last 4 hr of the 12-hr stimulation. After stimulation, cells were harvested and washed in staining buffer (PBS + 2% fetal bovine serum) with centrifugation at 800 g for 5 min. Cells were resuspended in BD FACS lysis buffer diluted in water at 1 : 10 and incubated for 10 min at room temperature. After washing, the cells were resuspended in 0Á5 ml PBS, and then 0Á5 ml BD Perm2 buffer diluted in water at 1 : 10 was added for 10 min at room temperature. After washing, the cell samples were stained for 30 min with antibodies targeting Tcell markers and intracellular cytokines ( Table 2 ). All antibodies were purchased from BD Biosciences with the exception of anti-mouse CD25 and anti-mouse Foxp3, which were purchased from Affymetrix (Santa Clara, CA) or eBioscience (San Diego, CA). After washing, the samples were fixed in a 2% formaldehyde solution. Foxp3 transcription factor staining was performed according to the manufacturers' instructions (Affymetrix, eBioscience). The CD4 + CD25 + and CD4 + CD25 + Foxp3 + cell populations were normalized by dividing the mean of stimulated cells by the mean of unstimulated cells. The samples were measured using a BD FACSCanto II flow cytometer (BD Biosciences), and 50 000-100 000 total events per sample were collected. The acquired data were then analysed with FLOWJO v10 software (FlowJo, Ashland, OR).
Tetramers and staining
The following tetramers were obtained through the NIH Tetramer Core Facility at Emory University (Atlanta, GA):
The MHC Class II tetramer was available as a premade reagent, and was labelled with phycoerythrin. The latter tetramer was designed based on previous studies that identified VETPIRNEW as an MHC class I influenza epitope in mice and humans. 27, 28 This peptide was synthesized by GenScript and shipped to the NIH Tetramer Core Facility for synthesis of tetramer, labelled with allophycocyanin. For tetramer staining experiments, mice were killed by cervical dislocation and spleens were collected into microcentrifuge tubes containing DMEM-10. Spleen cells were mechanically isolated by straining through 100-lm nylon mesh cell strainers. Red blood cells were removed using ACK lysis buffer followed by a washing step: cells were centrifuged at 8009g for 5 min at 4°using Allegra X-12R equipment (Beckman Coulter, Miami, FL). The splenic mononuclear cells were used for experiments at 1 9 10 6 cells/ml in 0Á1 ml DMEM-10 per well. For MHC class II experiments, cells were stained with 1 lg tetramer for 3 hr at 37°. The collected samples were washed in staining buffer with centrifugation at 8009g for 5 min. Samples were then stained with anti-mouse CD4-allophycocyanin and CD3-Alexa Fluor 700 (BD Biosciences) for 30 min at room temperature in the dark. For MHC class I experiments, cells were stained with 1 : 100 dilution of tetramer for 30 min at room temperature. After washing, these samples were stained with anti-mouse CD8-phycoerythrin and CD3-FITC (BD Biosciences) for 30 min at room temperature in the dark. All samples were washed once more and resuspended in 300 ll 2% formaldehyde in PBS. One hundred thousand total events were acquired using a Gallios flow cytometer (Beckmann-Coulter, Miami, FL) and data were analysed using FLOWJO v10 software (Treestar, Ashland OR).
Statistical analysis
GRAPHPAD PRISM 6 software (GraphPad, San Diego, CA) was used to perform numerical and statistical analyses including: (i) calculations of mean and error; (ii) KaplanMeier survival analyses for challenge experiments; (iii) two-way, two-tail analyses of variance with post-tests for T-cell stimulation experiments; and (iv) Student's t-tests. Differences were defined as statistically significant when P < 0Á05.
Results
Vaccine antigen design and influenza antigen-specific humoral immunity
We hypothesized that a broad-spectrum vaccine for influenza and anthrax could be created using the relatively conserved M2 and HA2 of influenza A virus as universal antigens delivered by detoxified anthrax oedema toxin. Fig. 1a ) and purified (Fig. 1b) an array of recombinant proteins in E. coli to be used for various vaccine formulations. Successful confirmation and expression of these proteins were confirmed by Western blot analysis. Representative blots are shown in Fig. 1(b) , confirming the reactivity of the vaccine candidates with anti-His, anti-Avian M2 and anti-EF antibodies. Immunized mice were evaluated for systemic antibody responses against recombinant M2 and 39M2e-HA2 antigens. Results in Fig. 2(a) showed that immunization with all vaccine formulations tested (M2, EFn-M2, EFn-M2 plus PA, EFn-39M2e-HA2 and EFn-39M2e-HA2 plus PA) stimulated strong reactivity against avian M2 by IgG1 and IgG2a antibodies. In addition, results in Fig. 2(b) showed that immunization with EFn-39M2e-HA2 or EFn-39M2e-HA2 plus PA induced high levels of serum IgG1 and IgG2a antibodies against recombinant 39M2e-HA2. Sera from mice immunized with EFn-M2 or EFn-M2 plus PA also reacted with recombinant 39M2e-HA2 protein, but to lesser extents. Mice immunized with recombinant, full-length M2 from avian influenza A virus had robust IgG1 and IgG2a responses similar to mice immunized with EFn-39M2e-HA2 or EFn-39M2e-HA2 plus PA. Moreover, inclusion of the centralized HA2 portion in the vaccine formulation elicited specific antibodies against HA2-region peptides from A/California/7/2009 (H1N1) virus (Fig. 2c) . However, only the EFn-39M2e-HA2 plus PA formulation eli- 
Protection against influenza viral challenge
Although all vaccine candidates elicited potent humoral responses, only immunization with EFn-39M2e-HA2 plus PA (three doses) reproducibly protected 100% of mice against PR8 influenza virus challenge, whereas other immunizations provided less striking degrees of protection (Fig. 3a) . As expected, all mice were protected when immunized with a one-time, low dose of PR8 at 50 PFU per mouse, with no weight loss associated with challenge. In addition, some protection was observed in mice immunized with EFn-39M2e-HA2 (56%) (Fig. 3a) . Next, protection by EFn-39M2e-HA2 plus PA was tested against challenge with CA09 virus. Immunization with EFn-39M2e-HA2 plus PA offered a protection rate of 88%, whereas immunization with a one-time, 50 PFU dose of CA09 was 100% protective as expected (Fig. 3b) . We next tested if sera from the EFn-39M2e-HA2 plus PA would protect naive mice from lethal challenge with PR8 virus. We transferred 200 ll of naive or immune sera to naive mice by intraperitoneal injection 1 day before challenge with PR8 virus. Only serum from mice vaccinated with a low-dose of PR8 virus transferred protective immunity against lethal challenge with PR8 virus (Fig. 3c) . Neither naive sera, nor sera from mice vaccinated with EFn-39M2e-HA2 with or without PA protected mice against lethal challenge with PR8 virus. This indicated that protective immunity by the EFn-39M2e-HA2 plus PA vaccine was not solely dependent on vaccine antigen-specific antibody responses. Two additional experiments employing passive transfer of naive or immune sera to mice by intravenous or intraperitoneal injections 1 day before challenge yielded the same results (data not shown). Furthermore, influenza virus neutralizing antibody titres in immune sera were measured by influenza virus microneutralization assay using MDCK cells. The results showed that immunization with EFn-39M2e-HA2 plus PA or without PA did not elicit neutralizing antibody responses against PR8 influenza virus (neutralization titres < 10). In contrast, sera from control mice vaccinated with PR8 virus had virus neutralization titres ≥ 2560 (Table 3) .
Immunity against anthrax in mice immunized with EFn-33M2e-HA2 plus PA After establishing that the vaccine candidates elicited specific immunity against influenza antigens, it was next tested if specific immunity against anthrax toxins was also developed. Therefore, we used our experience in performing anthrax toxin assays and neutralization assays to evaluate the ability of these sera to neutralize anthrax LeTx. Sera from BALB/c or A/J mice immunized with EFn39M2e-HA2 plus PA completely protected Raw 264.7 mouse macrophages from LeTx even at dilutions of 1 : 20 to 1 : 800 (Fig. 4a,b ). Even at a 1 : 6400 dilution, sera from A/J mice immunized with EFn-39M2e-HA2 plus PA provided strong protection, and challenged cells maintained 78% viability (Fig. 4b) . In contrast, sera from naive mice or from mice immunized with EFn-39M2e-HA2 were not protective at any dilution. Next, we confirmed anthrax toxin-specific antibody responses in A/J mice by ELISA. EFn-39M2e-HA2 plus PA induced systemic IgG responses against anthrax EF and PA proteins as measured by ELISA (Fig. 4c,d ). The response to PA occurred earlier and was stronger than the response to EF (0Á8 and 0Á2 lg/ml, respectively). Protective immunity was then assessed in mice challenged with B. anthracis Sterne spores. Mice immunized with three doses of EFn39M2e-HA2 plus PA (n = 8) were all protected against challenge with 5 9 10 4 spores, whereas animals immunized once with 50 spores via subcutaneous injection died by day 5 (Fig. 4e) . All mice were also protected against challenge after receiving one or two doses of EFn39M2e-HA2 plus PA, despite an increased challenge dose of 1Á8 9 10 5 spores (Fig. 4f) . Vaccination with 50 spores administered by subcutaneous injection did not provide any measurable immunity against anthrax (Fig. 4c-e) . Hence, the EFn-39M2e-HA2 plus PA formulation induced anthrax toxin neutralizing antibodies that potentially contributed to protecting mice from lethal challenge with B. anthracis Sterne spores.
T-cell immunity
As we still had an incomplete picture of how our vaccine candidate formulation provided protection against influenza challenge, we analysed vaccine-antigen-specific T responses by various methods. First, we measured antigen-stimulated responses by FACS. In mice immunized with EFn-39M2e-HA2 plus PA, there were significant increases in the percentages of CD4 + CD25 + FoxP3 + regulatory T (Treg) cells 29 in response to PA or M2e peptides (Fig. 5) compared with control mice. Upon PA stimulation, we found a significant difference in Treg cells between mice vaccinated with EFn-39M2e-HA2 plus PA and EFn-39M2e-HA2 alone. PMA was used as positive control for stimulation, and PMA also stimulated an increase in the percentage of Treg cells (Fig. 5b) . However, recombinant EF and HA2 peptides did not induce any Treg cell response (data not shown). To study the Tcell responses induced by HA2, we performed a cell proliferation assay using linear peptides of the chimeric HA2. None of the peptides induced proliferation of spleen cells from immunized mice or control mice (data not shown). Vaccine antigen-specific interleukin-2 (IL-2), IL-4, IL-6, IL-17, tumour necrosis factor-a, or interferon-c-positive T-cell responses were also not detected by FACS (data not shown). ELISPOT analyses following 2-day stimulations with 39M2e-HA2 confirmed that there were no significant inductions of IL-4 or interferon-c (data not shown). These results suggested that our EFn-39M2e-HA2 plus PA vaccine candidate launched a potentially immune-suppressive Treg cell response, in response to stimulation with M2e or PA.
To decipher what additional cellular immunities were elicited by our vaccine candidate, we used tetramer-staining, as a more sensitive approach to detect influenza-antigen-specific T responses. The M2 7-15 VETPIRNEW epitope has been identified as an HLA-B27 and HLA-B44 epitope in humans, 28 and an H-2Kd-restricted epitope in mice. 27 Hence, this was a logical peptide to use in probing influenza-specific responses. For completion, we also used a class II, restricted M2e-epitope tetramer that was already available from the NIH tetramer core facility. Using this methodology, we found that immunization with EFn-39M2e-HA2 plus PA elicited specific, M2e-epitope CD8 (4Á4%, Fig. 6a) and CD4 (1Á1%, Fig. 6b ) T-cell responses based on positive tetramer-binding. Furthermore, T-cell responses by immunized mice were statistically significantly different from those by naive mice as determined by Student's two-tailed t-tests, where P ≤ 0Á05 was considered significant.
In addition, to show that T-cell immunities were important in eliciting protection by our vaccine against lethal influenza challenge, we vaccinated wild-type, CD4 KO and CD8 KO C57BL/6 mice with PBS, PR8 or EFn39M2e-HA2 plus PA as before for BALB/c mice. Serum Table 3 . Micro-neutralization assay: neutralizing antibody titres against PR8 influenza virus
Groups
Titres (2 weeks after the third immunization)
EFn-39M2e-HA2/PA < 10 EFn-39M2e-HA2 antibody responses against 39M2e-HA2 were evaluated by ELISA. As shown in Fig. 7(a) , vaccinated CD4 KO mice produced low titres of antigen-specific IgG, IgG1 and Ig2a antibody responses against 39M2e-HA2, whereas vaccinated CD8 KO and C5BL/6 wild-type mice showed strong and equivalent antibody responses. These mice were then challenged with PR8 virus. Results showed that wild-type mice immunized with a low-dose of PR8 virus are completely protected from weight loss and death (Fig. 7b) . Wild-type mice immunized with EFn-39M2e-HA2 plus PA showed 100% survival against PR8 challenge, albeit some weight loss was observed. In contrast, the rate of protection by the EFn-39M2e-HA2 plus PA vaccine candidate in CD4 (57%) or CD8 (50%) KO mice greatly diminished.
Discussion
Our EFn-39M2e-HA2 plus PA vaccine formulation addresses the need for adequate vaccine strategies against influenza viruses and anthrax. Seasonal influenza virus epidemics account for 3-5 million cases of severe illness and between 250 000-500 000 deaths worldwide. 30 The influenza viruses that currently circulate in humans are mainly influenza A H1N1, H3N2 and B influenza viruses. As influenza viruses are constantly mutating, seasonal, trivalent or quadrivalent influenza vaccines must be produced annually. The 2009 H1N1 influenza virus pandemic reminded us of the need for a broad-range influenza vaccine. Furthermore, there is a threat that avian H5N1, H7N3 and H9N2 may adapt to humans in the near future. Cross-species transmissions of avian influenza viruses have already been shown to occur in pigs, horses, harbour seals, whales and mink. Outbreaks of severe disease and mortality have been observed in these mammals. 31 As production of influenza vaccines is time-consuming, the availability of an effective vaccine against a highly infectious, non-vaccine virus significantly lags. As a result, influenza viruses are a constant public health threat. The limitations of the current annual influenza vaccine has led to ongoing efforts to develop a vaccine that targets ubiquitous portions of the influenza virus so that the coverage of vaccination can (i) persist for multiple years and (ii) provide broad, cross-strain protection.
EFn-M2 and EFn-M2 plus PA formulations produced antibodies that reacted with avian M2 and cross-reacted with 39M2e-HA2 antigens, but it was disappointing that these responses were not more robust than immunizations with avian M2 alone. In this context, inclusion of EFn or PA in the formulation did not enhance immunogenicity of M2 as desired. These formulations were also PMA as positive control, 10 lg/ml of (iii) M2e peptides derived from A/New York/348/03 H1N1, or (iv) recombinant anthrax protective antigen (PA), or (v) recombinant oedema factor (EF) for 3 days before ICS and FACS analyses. Results represent mean + SEM for n = 15 mice (EFn39M2e-HA2 + PA and Control) and n = 13 mice (EFn-39M2e-HA2). Two-way, two-tail analysis of variance was performed and found that EFn-39M2e-HA2 + PA group compared with control group and EFn-39M2e-HA2 group significantly differed by immunization (P = 0Á0016; P = 0Á0206, respectively). not protective against lethal infection with PR8 virus. On the other hand, EFn-39M2e-HA2 and EFn-39M2e-HA2 plus PA formulations induced stronger antibody responses against influenza 39M2e-HA2, with strong antibody cross-reactivity to avian M2 and H1N1 HA2. The antibody responses induced by EFn-39M2e-HA2 and EFn-39M2e-HA2 plus PA were similar; however, vaccination with EFn-39M2e-HA2 was only 56% protective against influenza challenge. In contrast, vaccination with EFn-39M2e-HA2 plus PA protected 100% of mice from challenge with PR8 virus and 88% of mice from challenge with CA09 virus. Based on one of our previous studies, 32 we predict that this formulation can also protect against H3N2 viruses. We also predict, based on cross-reactive antibody responses to H5N1 avian M2 and HA2 that this vaccine may also protect against H5N1 viruses. Some studies have demonstrated that human monoclonal antibodies recognize conserve epitopes of HA2. Depending on their concentration, these monoclonal antibodies can neutralize the virus and protect mice from lethal challenge of influenza B viruses. 33 However, it is important to note that, in the current study, antigen-specific antibodies elicited by vaccination with our candidate vaccine could not neutralize the influenza virus as demonstrated in the passive antibody transfer and virus micro-neutralization experiments. These results were not unreasonable, as it has been shown that antibodies against M2 or HA2 do not have direct virus neutralizing or haemagglutinin inhibiting activity, 5,34-36 but somehow aid in clearing viral loads faster and inhibit the viral life cycle. Hence, we reasoned that T-cell responses elicited by our vaccine formulation play a major role in protection.
Indeed, we found that our EFn-39M2e-HA2 plus PA formulation induced CD4 and CD8 responses against epitopes within the highly conserved M2e region, and that CD4 and CD8 responses are important for survival against lethal challenge. Use of EFn and PA to deliver our vaccine may enhance T-cell responses by targeting antigen-presenting cells, such as macrophage for delivery and subsequent processing and presentation to T cells. We have previously shown that macrophage-like human and murine cells express high levels of anthrax toxin receptor capillary morphogenesis protein 2 (CMG2), and that these cells are susceptible to anthrax lethal toxin (LF with PA) and anthrax oedema toxin (EF with PA). 37 Hence, the combination of PA and EFn fused to influenza antigen will lead to the internalization of all these antigens into cells bearing anthrax toxin receptors, one of which is CMG2, which is well-expressed in macrophage. Infections with influenza A virus stimulate strong CD4 + and cytotoxic CD8 + responses for viral clearance, but these host responses can induce significant immunopathology and even death. 38 Hence, it is possible that in response to viral challenge, mice immunized with EFn-39M2e-HA2 plus PA may not only launch CD4 + and CD8 + responses for viral clearance, but also promote regulation of these responses by influenza-specific Treg cells. These Treg cells may be essential in reducing illness associated with inflammatory responses against influenza viral infection. It is known that in response to influenza viral infection, antigen-specific Treg cells migrate to lungs. 39, 40 The Treg cell response to influenza infection occurs even more quickly during a secondary infection, with increased Treg cell accumulation occurring faster in the lung-draining lymph nodes and lung parenchyma. 39 The influenza-specific Treg cell response precedes the effector T-cell response, 38, 39 and suppresses it by inhibiting proliferation of CD4 + and CD8 + cells. [38] [39] [40] Another interpretation of these results is that induction of Treg cell responses may not be ideal, and hence, Treg cell epitopes should be evaluated and targeted for deletion as a means to improve this vaccine. 41 This is beyond the scope of this work, but could be revisited in a future study.
It is possible that use of the detoxified anthrax toxins in our system may skew the immune responses. Activation of T-cell function is compromised by EdTx and LeTx; secretions of various cytokines are inhibited. 42 Oedema toxin inhibits secretion of IL-17, tumour necrosis factor-a, and interferon-c by stimulated T cells. 42 However, EFn in our vaccine formulations should be devoid of enzymatic activity and so, non-toxic when bound to PA. Furthermore, stimulation with full-length EF did not elicit a Treg cell response, whereas PA did. Hence, it is possible that PA is able to induce Treg cell responses, though this has not been reported in the literature, to our knowledge. Although the immunization with our vaccine candidate induces antibody responses against HA2 of two different strains of influenza virus, we did not find any stimulation of T cells by the HA2 peptides. Because antibody responses did not neutralize influenza as shown by passive transfer experiments, it may be that HA2 in our vaccine mainly induces antibody responses, which may target and prevent the membrane fusion process, so reducing replication of influenza, as has been reported by others. 3, 4, 43 Ultimately, the combination of humoral and CD4 and CD8 T-cell immunities elicited by the EFn-39M2e-HA2 plus PA formulation is protective against influenza virus. It is interesting to note that some mice (57%) were still able to survive challenge in the absence of CD4 T cells (Fig. 7) . These mice also had poor antibody responses against vaccine antigens. Hence, it is possible our vaccine was able to elicit T helper-independent CD8 T-cell responses that offered some level of protection to challenged mice. 44 The ultimate goal of our research is to generate a universal influenza vaccine, so future study should further characterize protection against a broader panel of both older and more recently circulating influenza virus strains. A future study is needed to better characterize The EFn-39M2e-HA2 plus PA vaccine also elicited potent, neutralizing antibody responses against anthrax toxins. These responses contributed to the protection observed in mice challenged with anthrax spores. The immunized mice all survived, without any signs of illness or discomfort noted. Hence, the vaccine offered complete protection against anthrax disease. In short, the dual vaccine formulation we described above may provide ideal protection against two very important public health concerns.
